Global Low Molecular Weight Heparin Market – Global Industry Insights

Low Molecular Weight Heparins (LMWH) are a form of pharmacological anticoagulant intervention which are derived from UFH by chemical or enzymatic depolymerisation to yield fragments that are around one third the size of heparin.  Low molecular weight heparin is used for prophylaxis of deep vein thrombosis and pulmonary embolism, or thrombosis occurring in a broad spectrum of clinical indications, including general or orthopaedic surgery, neurosurgery, trauma, unstable angina, and myocardial infarction. LMWHs are However, it is associated with higher anticoagulant effect and provides higher bioavailability after subcutaneous administration, as compared to unfractionated heparin (UFH), for thromboembolic indications. Low molecular weight heparin is the most suitable anticoagulant in case of complicated pregnancy, as it eliminates risk of crossing the placental membrane.   

The global low molecular weight heparin market size was valued at US$ 2,882.6 Mn in 2017, and is expected to witness a CAGR of 6.7% during the forecast period (2018 – 2026).

Global Low Molecular Weight Heparin Market Share (%), By Drug: 2018 & 2026

Low Molecular Weight Heparin  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing Advantages of Low Molecular Weight Heparin over Unfractionated Heparin is expected to drive the Market Growth during the Forecast Period

Unfractionated heparin or standard heparin varies in action from patient to patient. Thus, it can only be administered to hospitalized patients under monitoring, while low molecular weight heparins (LMWHs) can be used subcutaneously once a day, without requirement for monitoring.

Furthermore, LMWHs have more predictable pharmacokinetic properties as compared to unfractionated heparin (UFH), which allows LMWHs to be administered in fixed doses and without the need for dose adjustment based on laboratory monitoring.

The mean molecular weight of LMWH fractions is around 3,500–8,000 daltons, as compared with 15,000 daltons in unfractionated material. As low-molecular-weight fractions of heparin react less with platelets than high-molecular-weight fractions, it was also expected that LMWH would less often induce immuno-allergic thrombocytopenia, a severe side-effect of UFH that is often complicated by arterial thrombosis.

Such advantages of low molecular weight heparin over unfractionated heparin are driving growth of the low molecular weight heparin market. Furthermore, properties such as better bioavailability, predictable dose response, and longer plasma half-life than unfractionated heparin, makes low molecular weight heparin a better candidate for anticoagulant therapy. This in turn is fuelling demand for low molecular weight heparin, and thus it is expected to boost the market growth over the forecast period. 


Global Low Molecular Weight Heparin Market Share (%), By Application: 2018 & 2026

Low Molecular Weight Heparin  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing Introduction of Biosimilar LMWH Anticoagulants Globally is Expected to Aid in the Market Growth  

LMWH usage is expected to increase over the forecast period, due to a number of other non-anticoagulant properties. These include anti-tumor, anti-inflammatory, and anti-proliferative actions (in pathologies such as nephrotic syndrome and Alzheimer’s disease). The patents of LMWHs have now expired. However, the market potential for LMWHs is witnessing growth, owing to increasing use in a number of Western European countries and emerging economies  and its potential indications, such as thromboprophylaxis, Venous thromboembolism (VTE), anticoagulation treatment during pregnancy, among others. Enoxaparin is the bestselling LMWH worldwide. Therefore, pharmaceutical companies in many countries are focused on producing generic forms of LMWH.

According to Hospital Pharmacy Europe: November 2016; several pharmaceutical companies produce copies of enoxaparin in Argentina, Brazil, Chile, Columbia, Egypt, Ecuador, Georgia, India, Morocco, Myanmar, Peru, The Philippines, South Korea, Tunisia, Turkey, the U.S., and Venezuela. Pharmaceutical companies from these countries are also engaged in research and development activities to produce a biosimilar of enoxaparin. This generates high competition in the LMWHs market.

Pharmaceutical companies produced either as biosimilars or named generic versions of the branded LMWH. Specifically, copies of enoxaparin are available in North and Latin America and Asian countries. In Australia and Europe, regulatory bodies developed specific requirements for approval of biosimilar LMWHs. Africa is currently not included so far in this development.

Adverse effects of low molecular weight heparin during treatment is a major restraint for growth of the LMWH market. Heparin induced thrombocytopenia (HIT), an adverse reaction occurring during treatment with heparin, is associated with inconsistent increase in the clotting causing further complications. Heparin-induced thrombocytopenia (HIT) is an adverse reaction that can occur during treatment with heparin. Increasing epidemic of Heparin-induced thrombocytopenia (HIT) due to application of heparin is restricting the growth of market.

For instance, according to the data published in American Society of Hematology in 2017, Heparin-induced thrombocytopenia (HIT) is heparin’s most clinically relevant non-hemorrhagic complication. Furthermore, adults receiving heparin formulation for medical or general surgical indications are at higher risk for HIT than pediatric or obstetric patients.

Among regions, Europe is expected to be the most lucrative region in the low molecular weight heparin market over the forecast period, due to low molecular weight heparin being majorly used heparin type in Europe, owing to its advantage over unfractionated heparin. Low molecular weight heparins such as enoxaparin, dalteparin, tinzaparin, and certoparin are majorly sold heparin drugs in Europe.

Government regulatory authorities are imposing regulations on the application of LMWHs biosimilars and its approval process. Increasing engagement of regulatory bodies in authorizing LMWH biosimilar in these markets is expected to drive growth of the market. For instance, in July 2016, the European Medicines Agency (EMA) authorized the introduction and marketing of Thorinane and Inhixa, biosimilars of Low Molecular Weight Heparin (LMWH), enoxaparin.

In 2014, the Committee for Medicinal Products for Human Use (CHMP) of the EMA issued the ‘Guideline on similar biological medicinal products’ CHMP/437/04 Rev. 1, with the purpose of describing the concept of similar biological medicinal products and to outline the general principles to be applied.  

Key players operating in the low molecular weight heparin market include, Pfizer, Inc., LEO Pharma A/S, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, Changzhou Qianhong Biopharma, and Intrapharm Laboratories.

Low Molecular Weight Heparin (LMWH) has several advantages over other heparin such as longer and more predictable activity than Unfractionated Heparin (UFH) and can be self-administrated at home via subcutaneous injection, reducing or eliminating hospital stays, thereby no regular blood monitoring required. Furthermore, heparins do not cross the placenta or harm the fetus, so they are the preferred anticoagulants for pregnant women who experience or who are at heightened risk of – blood clots. These advantages make LMWH as the most preferred heparin in inhibiting clotting factors.

Market Dynamics

Increasing number of people are being affected with Deep Vein Thrombosis (DVT) which will subsequently increase demand for LMWH. For instance, according to National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention (CDC), February 2018; the precise number of people affected by DVT/PE is unknown, although as many as 900,000 people could be affected (1 to 2 per 1,000) each year in the U.S.

Furthermore, increasing engagement of government healthcare regulatory bodies in developing and delivering effective and cost-effective low molecular weight heparin molecule products in the market is expected to propel the growth of the market. For instance, in 2014, American Society of Health-System Pharmacists (ASHP) issued the policy for safe and effective use of heparin in neonatal patients thereby supporting the development and use of nationally standardized concentrations of heparin when used for maintenance and flush of peripheral and central venous lines in neonatal patients.  

Key features of the study:

  • This report provides in-depth analysis of low molecular weight heparin market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, low molecular weight heparin approval & launch, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global low molecular weight heparin market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
  • Key companies covered as part of this study include, Pfizer, Inc., LEO Pharma A/S, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, Changzhou Qianhong Biopharma, and Intrapharm Laboratories.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future drug launch, manufacturing up-gradation, market expansion, and marketing tactics
  • The global low molecular weight heparin market report caters to various stakeholders in this industry including investors, suppliers, low molecular weight heparin based product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the low molecular weight heparin market.

Detailed Segmentation:

  • Global Low Molecular Weight Heparin Market, By Drug:
    • Enoxaparin
    • Dalteparin
    • Nadroparin
    • Bemiparin
    • Tinzaparin
    • Others
  • Global Low Molecular Weight Heparin Market, By Packaging:
    • Multi-vials
    • Prefilled Syringes     
  • Global Low Molecular Weight Heparin Market, By Application:
    • Deep Vein Thrombosis
    • Acute Coronary Syndrome (ACS)
    • Pulmonary Embolism
    • Atrial Fibrillation
  • Global Low Molecular Weight Heparin Market, By End Use:
    • Hospitals
      • Private
      • Public
    • Clinics
    • Home
  • Global Low Molecular Weight Heparin Market, By Geography:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug:
        • Enoxaparin
        • Dalteparin
        • Nadroparin
        • Bemiparin
        • Tinzaparin
        • Others
      • By Packaging
        • Multi-vials
        • Prefilled Syringes
      • By Application:
        • Deep Vein Thrombosis
        • Acute Coronary Syndrome (ACS)
        • Pulmonary Embolism
        • Atrial Fibrillation
      • By End Use:
        • Hospitals
          • Private
          • Public
        • Clinics
        • Home
    • Europe
      • By Country:
        • Germany
        • France
        • Italy
        • UK
        • Spain
        • Russia
        • Rest of Europe
      • By Drug:
        • Enoxaparin
        • Dalteparin
        • Nadroparin
        • Bemiparin
        • Tinzaparin
        • Others
      • By Packaging
        • Multi-vials
        • Prefilled Syringes
      • By Application:
        • Deep Vein Thrombosis
        • Acute Coronary Syndrome (ACS)
        • Pulmonary Embolism
        • Atrial Fibrillation
      • By End Use:
        • Hospitals
          • Private
          • Public
        • Clinics
        • Home
    • Asia Pacific
      • By Country:
        • China
        • India
        • Japan
        • South Korea
        • Australia
        • Rest of Asia Pacific
      • By Drug:
        • Enoxaparin
        • Dalteparin
        • Nadroparin
        • Bemiparin
        • Tinzaparin
        • Others
      • By Packaging
        • Multi-vials
        • Prefilled Syringes
      • By Application:
        • Deep Vein Thrombosis
        • Acute Coronary Syndrome (ACS)
        • Pulmonary Embolism
        • Atrial Fibrillation
      • By End Use:
        • Hospitals
          • Private
          • Public
        • Clinics
        • Home
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug:
        • Enoxaparin
        • Dalteparin
        • Nadroparin
        • Bemiparin
        • Tinzaparin
        • Others
      • By Packaging
        • Multi-vials
        • Prefilled Syringes
      • By Application:
        • Deep Vein Thrombosis
        • Acute Coronary Syndrome (ACS)
        • Pulmonary Embolism
        • Atrial Fibrillation
      • By End Use:
        • Hospitals
          • Private
          • Public
        • Clinics
        • Home
    • Latin America
      • By Country:
        • Brazil
        • Argentina
        • Mexico
        • Rest of Latin America
      • By Drug:
        • Enoxaparin
        • Dalteparin
        • Nadroparin
        • Bemiparin
        • Tinzaparin
        • Others
      • By Packaging
        • Multi-vials
        • Prefilled Syringes
      • By Application:
        • Deep Vein Thrombosis
        • Acute Coronary Syndrome (ACS)
        • Pulmonary Embolism
        • Atrial Fibrillation
      • By End Use:
        • Hospitals
          • Private
          • Public
        • Clinics
        • Home
    • Africa
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug:
        • Enoxaparin
        • Dalteparin
        • Nadroparin
        • Bemiparin
        • Tinzaparin
        • Others
      • By Packaging
        • Multi-vials
        • Prefilled Syringes
      • By Application:
        • Deep Vein Thrombosis
        • Acute Coronary Syndrome (ACS)
        • Pulmonary Embolism
        • Atrial Fibrillation
      • By End Use:
        • Hospitals
          • Private
          • Public
        • Clinics
        • Home
  • Company Profiles
    • Pfizer, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments
      • Strategies
    • LEO Pharma A/S
    • Sanofi S.A.
    • Teva Pharmaceutical Industries Ltd.
    • Amphastar Pharmaceuticals Inc.
    • Abbott Laboratories
    • Aspen Pharmacare Holdings
    • Laboratorios Farmaceuticos ROVI SA
    • Changzhou Qianhong Biopharma
    • Intrapharm Laboratories

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug
      • Market Snippet, By Packaging
      • Market Snippet, By Application
      • Market Snippet, By End Use
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Epidemiology
    • Key Developments
    • Strategic Acquisitions   
    • Advantages of LMWH over UFH
    • Cost-effectiveness of LMWH vs. UFH
    • Shortage of Enoxaparin & Estimated Resupply Dates
    • Drug Delivery Systems
    • Regulatory Scenario
    • Reimbursement Scenario
    • Buy-and-bill and White Bagging Channel
    • PEST Analysis
  4. Global Low Molecular Weight Heparin Market, By Drug, 2018 - 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 - 2026
      • Segment Trends
    • Enoxaparin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Dalteparin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Nadroparin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Bemiparin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Tinzaparin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  5. Global Low Molecular Weight Heparin Market, By Packaging, 2018 - 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 - 2026
      • Segment Trends
    • Multi-vials
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Prefilled Syringes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  6. Global Low Molecular Weight Heparin Market, By Application, 2018 - 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 - 2026
      • Segment Trends
    • Deep Vein Thrombosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Acute Coronary Syndrome (ACS)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Pulmonary Embolism
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Atrial Fibrillation
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  7. Global Low Molecular Weight Heparin Market, By End Use, 2018 - 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 - 2026
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
        • Private
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
        • Public
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Home
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  8. Global Low Molecular Weight Heparin Market, By Region, 2018 - 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 - 2026
    • North America
      • Market Size and Forecast, By Drug, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Packaging, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By End Use, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Packaging, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By End Use, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Packaging, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By End Use, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Packaging, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By End Use, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Packaging, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By End Use, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drug, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Packaging, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By End Use, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  9. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Pfizer, Inc.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • LEO Pharma A/S
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Sanofi S.A.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Amphastar Pharmaceuticals Inc.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Aspen Pharmacare Holdings
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Laboratorios Farmaceuticos ROVI SA
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Changzhou Qianhong Biopharma
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Intrapharm Laboratories
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Abbott Laboratories
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
  10. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 44 market data tables and 39 figures on "Low Molecular Weight Heparin Market - Global forecast to 2026”.